High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson’s disease
Proceedings of the National Academy of Sciences · 15.10.2024 · 121 (42)
DOI: 10.1073/pnas.2406009121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.10.2024. Verfasst von Darian Williams und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850. Hauptthemen laut MEDLINE: Glucosylceramidase, Gaucher Disease, Parkinson Disease, High-Throughput Screening Assays. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research (MJFF).
Abstract (Originalsprache)
Glucocerebrosidase (GCase) is implicated in both a rare, monogenic disorder (Gaucher disease, GD) and a common, multifactorial condition (Parkinson’s disease, PD); hence, it is an urgent therapeutic target. To identify correctors of severe protein misfolding and trafficking obstruction manifested by the pathogenic L444P-variant of GCase, we developed a suite of quantitative, high-throughput, cell-based assays. First, we labeled GCase with a small proluminescent HiBiT peptide reporter tag, enabling quantitation of protein stabilization in cells while faithfully maintaining target biology. TALEN-based gene editing allowed for stable integration of a single HiBiT- GBA1 transgene into an intragenic safe-harbor locus in GBA1 -knockout H4 (neuroglioma) cells. This GD cell model was amenable to lead discovery via titration-based quantitative high-throughput screening and lead optimization via structure–activity relationships. A primary screen of 10,779 compounds from the NCATS bioactive collections identified 140 stabilizers of HiBiT-GCase-L444P, including both pharmacological chaperones (ambroxol and noninhibitory chaperone NCGC326) and proteostasis regulators (panobinostat, trans-ISRIB, and pladienolide B). Two complementary high-content imaging-based assays were deployed to triage hits: The fluorescence-quenched substrate LysoFix-GBA captured functional lysosomal GCase activity, while an immunofluorescence assay featuring antibody hGCase-1/23 directly visualized GCase lysosomal translocation. NCGC326 was active in both secondary assays and completely reversed pathological glucosylsphingosine accumulation. Finally, we tested the concept of combination therapy by demonstrating synergistic actions of NCGC326 with proteostasis regulators in enhancing GCase-L444P levels. Looking forward, these physiologically relevant assays can facilitate the identification, pharmacological validation, and medicinal chemistry optimization of small molecules targeting GCase, ultimately leading to a viable therapeutic for GD and PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850.
- Molecular Neurogenetics Section, Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892.
- Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
- Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
ORCID-Profile: Tiffany Chen, Sha Zhu, Raul Calvo, Alexandra Gehrlein, Kimberly Wong, David J Vocadlo, Juan J Marugan, Ellen Sidransky, Mark J Henderson, Yu Chen
Förderung
- Michael J. Fox Foundation for Parkinson's Research (MJFF)
Zitieren
APA
Williams, D., Glasstetter, L. M., Jong, T. T., Chen, T., Kapoor, A., Zhu, S., Zhu, Y., Calvo, R., Gehrlein, A., Wong, K., Hogan, A. N., Vocadlo, D. J., Jagasia, R., Marugan, J. J., Sidransky, E., Henderson, M. J., & Chen, Y. (2024). High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson’s disease. Proceedings of the National Academy of Sciences, 121(42). https://doi.org/10.1073/pnas.2406009121
Vancouver
Williams D, Glasstetter LM, Jong TT, Chen T, Kapoor A, Zhu S, et al. High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson’s disease. Proceedings of the National Academy of Sciences. 2024;121(42). doi:10.1073/pnas.2406009121
BibTeX
@article{Williams2024,
author = {Williams, Darian and Glasstetter, Logan M and Jong, Tiffany T and Chen, Tiffany and Kapoor, Abhijeet and Zhu, Sha and Zhu, Yanping and Calvo, Raul and Gehrlein, Alexandra and Wong, Kimberly and Hogan, Andrew N and Vocadlo, David J and Jagasia, Ravi and Marugan, Juan J and Sidransky, Ellen and Henderson, Mark J and Chen, Yu},
title = {High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson’s disease},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {42},
doi = {10.1073/pnas.2406009121}
}
EUVIMED